Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models

Prostate cancer (PCa) relies in part on AR-signaling for disease development and progression. Earlier, we developed drug candidate galeterone, which advanced through phase 2-clinical trials in treating castration-resistant PCa (CRPC). Subsequently, we designed, synthesized, and evaluated next-genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Elizabeth, Thankan, Retheesh S., Purushottamachar, Puranik, Huang, Weiliang, Kane, Maureen A., Zhang, Yuji, Ambulos, Nicholas P., Weber, David J., Njar, Vincent C. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454942/
https://www.ncbi.nlm.nih.gov/pubmed/36078112
http://dx.doi.org/10.3390/cells11172699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454942/
https://www.ncbi.nlm.nih.gov/pubmed/36078112
http://dx.doi.org/10.3390/cells11172699

Ejemplares similares